Pharmaceutical Executive Daily: Alnylam Invests $250 Million in Manufacturing Facility

Jan 06, 07:22 PM

Headliner
Share
Subscribe

In today’s Pharmaceutical Executive Daily, Eli Lilly and Nimbus Therapeutics announce a major licensing deal for oral obesity treatments, Hoth Therapeutics expands its intellectual property portfolio with new provisional patents, and Alnylam commits $250 million to expand manufacturing capabilities in Massachusetts.

Share
Subscribe
Next
Pharmaceutical Executive Daily: Amgen Acquires Dark Blue Therapeutics for $840 Million
Top episodes
Healthcare Marketing Strategies for Reaching Diverse Audiences
by Pharmaceutical Executive
Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals
by Pharmaceutical Executive
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
by Pharmaceutical Executive